Home > Quotes > VRTX
VRTX

Vertex Pharmaceuticals Incorporated Common Stock Quote & Summary Data

$84.39
*  
2.36
2.72%
Get VRTX Alerts
*Delayed - data as of Apr. 29, 2016  -  Find a broker to begin trading VRTX now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Vertex Pharmaceuticals Incorporated Common Stock Intraday Chart




News for VRTX

Shares Traded

Trading Range

Intraday Last 52 Weeks
High $ 86.23 $ 143.45
Low $ 83.40 $ 75.90

The current last sale of $84.39 is 11.19% Higher thanthe 52 week low.

P/E Ratio

ETFs with VRTX as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
4.56% PowerShares Dynamic Biotech &Genome (PBE) -8.63 (-17.62%)
4.03% Market Vectors Biotech ETF (BBH) -10.90 (-9.08%)
3.61% iShares Nasdaq Biotechnology Index Fund (IBB) -46.70 (-14.50%)
1.51% SPDR Series Trust SPDR S&P Biotech ETF (XBI) -13.75 (-19.95%)
0.13% PowerShares FTSE RAFI US 1500 Small-Mid Portfolio (PRFZ) +0.88 (0.90%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. We use precision medicine approaches with the goal of creating transformative drugs for patients in specialty markets. Our business is focused on developing and commercializing therapies for the treatment of cystic fibrosis, or CF, and advancing our research and development programs in other indications, while maintaining our financial strength. Cystic Fibrosis Our goal is twofold: to develop treatment regimens that will provide benefits to as many patients with CF as possible and to enhance those benefits. Our two marketed medicines are ORKAMBI and KALYDECO, which are approved to treat patients with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator, or CFTR, gene.  ... More ...  

Risk Grade

Where does VRTX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Consensus Recommendation

Research Brokers before you trade

Want to trade FX?